Late-life depression: Rationalizing pharmacological treatment options

Gerontology

Volumn 48, Issue 6, 2002, Pages 392-400

  Montgomery, Stuart A ^a,b  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Antidepressants, efficacy; Antidepressants, pharmacokinetics; Antidepressants, safety; Depression, late life

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE;

AGED; ARTICLE; CONTROLLED STUDY; DEFENSE MECHANISM; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HUMAN; LIFESTYLE; MALE; PRIORITY JOURNAL;

AGED; ANTIDEPRESSIVE AGENTS; DEPRESSION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; POLYPHARMACY; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS;

EID: 0036976832     PISSN: 0304324X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065502     Document Type: Article

References (112)

1. Blazer D, Hughes DC, George LK: The epidemiology of depression in an elderly community population. Gerontologist 1987;27:281-287.
2. Johnson J, Weissman MM, Klerman GL: Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992;267:1478-1483.
3. Judd LL, Rapaport MH, Paulus MP, Brown JL: Subsyndromal symptomatic depression: A new mood disorder? J Clin Psychiatry 1994; 55(suppl):18-28.
4. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, Greenfield S, Ware CJ: The functioning and well-being of depressed patients: Results from the medical outcomes study. JAMA 1989;262:914-919.
5. Meyers BS, Bruce ML: Outcomes for antidepressant trials in late-life depression. Psychopharmacol Bull 1997;33:701-705.
6. Ormel J, Kempen GI, Deeg DJ, Brilman EI, van Sonderen E, Relyveld J: Functioning, well-being, and health perception in late middle-aged and older people: Comparing the effects of depressive symptoms and chronic medical conditions. J Am Geriatr Soc 1998;46:39-48.
7. Henriksson MM, Marttunen MJ, Isometsa ET, Heikkinen ME, Aro HM, Kuoppasalmi KI, Lonnqvist JK: Mental disorders in elderly suicide. Int Psychogeriatr 1995;7:275-286.
8. Alexopoulos GS, Bruce ML, Hull J, Sirey JA, Kakuma T: Clinical determinants of suicidal ideation and behavior in geriatric depression. Arch Gen Psychiatry 1999;56:1048-1053.
9. Conwell Y, Lyness JM, Duberstein P, Cox C, Seidlitz L, DiGiorgio A, Caine ED: Completed suicide among older patients in primary care practices: A controlled study. J Am Geriatr Soc 2000;48:23-29.
10. Montgomery SA, Beekman ATF, Sadavoy J, Salzman C, Thompson C, Zisook S: Consensus statement on depression in the elderly. J Clin Psychiatry 2000;2:46-52.
11. Koenig HG: Late-life depression: How to treat patients with comorbid chronic illness. Interview by Alice V. Luddington. Geriatrics 1999; 54:56-61.
12. Montano CB: Primary care issues related to the treatment of depression in elderly patients. J Clin Psychiatry 1999;60(suppl 20):45-51.
13. Flint AJ, Rifat SL: Maintenance treatment for recurrent depression in late life. A four-year outcome study. Am J Geriatr Psychiatry 2000; 8:112-116.
14. World Health Organisation: Health for all database. European region. European Office. 1998. Ref Type: Generic.
15. Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY, Kupfer DJ, Reynolds CF III: Serotonin in aging, late-life depression, and Alzheimer's disease: The emerging role of functional imaging. Neuropsychopharmacology 1998;18:407-430.
16. Blazer D: EURODEP Consortium and late-life depression. Br J Psychiatry 1999;174:284-285.
17. Prince MJ, Beekman AT, Deeg DJ, Fuhrer R, Kivela SL, Lawlor BA, Lobo A, Magnusson H, Meller I, van Oyen H, Reischies F, Roelands M, Skoog I, Turrina C, Copeland JR: Depression symptoms in late life assessed using the EURO-D scale. Effect of age, gender and marital status in 14 European centres. Br J Psychiatry 1999;174:339-345.
18. Robertson MM, Katona CLE: Depression and Physical Illness. Chichester, Wiley, 1997.
19. Alexopoulos GS, Abrams RC: Depression in Alzheimer's disease. Psychiatr Clin North Am 1991;14:327-340.
20. Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T: The course of geriatric depression with 'reversible dementia': A controlled study. Am J Psychiatry 1993;150:1693-1699.
21. Cole MG: The prognosis of depression in the elderly. Can Med Assoc J 1990;142:633-639.
22. Lebowitz BD: Diagnosis and treatment of depression in late life. Am J Geriatr Psychiatry 1996;4:3-6.
23. Beekman AT, Penninx BW, Deeg DJ, Ormal J, Braam AW, van Tilburg W: Depression and physical health in later life: Results from the Longitudinal Aging Study Amsterdam (LASA). J Affect Disord 1997;46:219-231.
24. Dunbar GC, Fuell DL: The anti-anxiety and anti-agitation effects of paroxetine in depressed patients. Int Clin Psychopharmacol 1992; 6(suppl 4):81-90.
25. Schultz SK, Castillo CS, Kosier JT, Robinson RG: Generalized anxiety and depression. Assessment over 2 years after stroke. Am J Geriatr Psychiatry 1997;5:229-237.
26. Sheehan D, Dunbar GC, Fuell DL: The effect of paroxetine on anxiety and agitation associated with depression. Psychopharmacol Bull 1992;28:139-143.
27. Montgomery SA: Therapy choices for late-life depression. Primary Care Companion to J Clin Psychiatry 2000;2:39-43.
28. Krishnan KR, Gadde KM: The pathophysiological basis for late life depression: Imaging studies of the brain. Am J Geriatr Psychiatry 1996;4:22-33.
29. Bakish D: The patient with comorbid depression and anxiety: The unmet need. J Clin Psychiatry 1999;60(suppl 6):20-24.
30. Robinson RG, Chemerinski E, Jorge R: Pathophysiology of secondary depressions in the elderly. J Geriatr Psychiatry Neurol 1999;12: 128-136.
31. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders DSM-IV. Washington, APA, 1994.
32. Sunderland T, Lawlor BA, Molchan SE, Martinez RA: Depressive syndromes in the elderly: Special concerns. Psychopharmacol Bull 1988; 24:567-576.
33. Burrows AB, Satlin A, Salzman C, Nobel K, Lipsitz LA: Depression in a long-term care facility: Clinical features and discordance between nursing assessment and patient interviews. J Am Geriatr Soc 1995;43:1118-1122.
34. Beekman AT, Deeg DJ, Smit JH, van Tilburg W: Predicting the course of depression in the older population. Results from a community-based study in The Netherlands. J Affect Disord 1995;34:41-49.
35. Prince MJ, Harwood RH, Thomas A, Mann AH: A prospective population-based cohort study of the effects of disablement and social milieu on the onset and maintenance of late-life depression. The Gospel Oak Project VII. Psychol Med 1998;28:337-350.
36. Lebowitz BD, Pearson JL, Schneider LS, Reynolds CF III, Alexopoulos GS, Bruce ML, Conwell Y, Katz IR, Meyers BS, Morrison MF, Mossey J, Niederehe G, Parmelee P: Diagnosis and treatment of depression in late life. Consensus statement update. JAMA 1997;278: 1186-1190.
37. Rose VL: Consensus statement update on depression in late life is issued by the NIH. Am Fam Physician 1998;57:2013.
38. Blazer D, Williams CD: Epidemiology of dysphoria and depression in an elderly population. Am J Psychiatry 1980;137:439-444.
39. Streim JE, Oslin DW, Katz IR, Smith BD, DiFilippo S, Cooper TB, Ten Have T: Drug treatment of depression in frail elderly nursing home residents. Am J Geriatr Psychiatry 2000; 8:150-159.
40. Altamura AC, Mauri MC, Rudas N, Carpiniello B, Montanini R, Perini M, Scapicchio PL, Hadjchristos C, Carucci G, Minervini M: Clinical activity and tolerability of trazodone, mianserin, and amitriptyline in elderly subjects with major depression: A controlled multicenter trial. Clin Neuropharmacol 1989;12(suppl 1):S25-S33.
41. Branconnier RJ, Cole JO, Ghazvinian S, Rosenthal S: Treating the depressed elderly patient: The comparative behavioral pharmacology of mianserin and amitriptyline. Adv Biochem Psychopharmacol 1982;32:195-212.
42. Cohn JB, Varga L, Lyford A: A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients. J Clin Psychiatry 1984;45:68-72.
43. Gerner R, Estabrook W, Steuer J, Jarvik L: Treatment of geriatric depression with trazodone, imipramine, and placebo: A double-blind study. J Clin Psychiatry 1980;41:216-220.
44. Hoyberg OJ, Maragakis B, Mullin J, Norum D, Stordall E, Ekdahl P, Ose E, Moksnes KM, Sennef C: A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996; 93:184-190.
45. Merideth CH, Feighner JP, Hendrickson G: A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients. J Clin Psychiatry 1984;45:73-77.
46. Nair NP, Amin M, Holm P, Katona C, Klitgaard N, Ng Ying Kin NM, Kragh-Sørensen P, Kuhn H, Leek CA, Stage KB: Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo. J Affect Disord 1995;33:1-9.
47. Tignol J, Pujol-Domenech J, Chartres JP, Léger JM, Pletan Y, Tonelli I, Tournoux A, Pezous N: Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand 1998;97:157-165.
48. Petracca G, Tesón A, Chemerinski E, Leiguarda R, Starkstein SE: A double-blind placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1996;8:270-275.
49. Reifler BV, Teri L, Raskind M, Veith R, Barnes R, White E, McLean P: Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 1989;146:45-49.
50. Jacobs SC, Nelson JC, Zisook S: Treating depressions of bereavement with antidepressants. A pilot study. Psychiatr Clin North Am 1987; 10:501-510.
51. Pasternak RE, Reynolds CF III, Schlernitzauer M, Hoch CC, Buysse DJ, Houck PR, Perel JM: Acute open-trial nortriptyline therapy of bereavement-related depression in late life. J Clin Psychiatry 1991;52:307-310.
52. Reynolds CF III, Miller MD, Pastermak RE, Frank E, Peral JM, Cornes C, Houck PR, Mazumdar S, Dew MA, Kupfer D: Treatment of bereavement-related major depressive episodes in later life: A controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. Am J Psychiatry 1999;156:202-208.
53. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D: Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994;9:47-53.
54. Glassman AH, Bigger JT: Cardovascular effects of therapeutic doses of tricyclic antidepressants. A review. Arch Gen Psychiatry 1981;38:815-820.
55. Roose SP, Glassman AH: Antidepressant choice in the patient with cardiac disease: Lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry 1994; 55(suppl A):83-87.
56. Roose SP, Suthers KM: Antidepressant response in late-life depression. J Clin Psychiatry 1998;59(suppl 10):4-8.
57. DeVane CL: Pharmacokinetics of the newer antidepressants: Clinical relevance. Am J Med 1994;97:13S-23S.
58. Henry JA, Alexander CA, Sener EK: Relative mortality from overdose of antidepressants. BMJ 1995;310:221-224.
59. Barbey JT, Roose SP: SSRI safety in overdose. J Clin Psychiatry 1998;59(suppl 15):42-48.
60. Mittmann N, Herrmann N, Einarson TR, Busto UE, Lanctot KL, Liu BA, Shulman KI, Silver IL, Narango CA, Shear NH: The efficacy, safety and tolerability of antidepressants in late life depression: A meta-analysis. J Affect Disord 1997;46:191-217.
61. Hutchinson DR, Tong S, Moon CAL, et al: Paroxetine in the treatment of elderly depressed patients in general practice: A double-blind comparison with amitriptyline. Int Clin Psychopharmacol 1992;6(suppl 4):43-51.
62. Geretsegger C, Stuppaeck CH, Mair M, Platz T, Fartacek R, Heim M: Multicenter double-blind study of paroxetine and amitriptyline in elderly depressed inpatients.. Psychopharmacology (Berl) 1995;119:277-281.
63. Guillibert E, Pelicier Y, Archambault JL, Chabanne S, Clerc GE, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y: A double-blind multicentre study of paroxetine vs. clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989;80:132-134.
64. Dunner DL, Cohn JB, Walshe T, Cohn CK, Feighner JP, Fieve RR, Halikas JP, Hartford JT, Hearst ED, Settle EL: Two combined multi-centre double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992;53:57-60.
65. Katona CL, Hunter BN, Bray J: A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998;13:100-108.
66. Mulsant BH, Pollock BG, Nebes RD, Miller MD, Little JT, Stack J, Houck PR, Bensasi S, Mazumdar S, Reynolds CF III: A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999; 60(suppl 20):16-20.
67. Dorman T: Sleep and paroxetine: A comparison with mianserin in elderly depressed patients. Int Clin Psychopharmacol 1992;6:53-58.
68. Ravindran AV, Judge R, Hunter BN, Bray J, Hunter NH: A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. J Clin Psychiatry 1996;58: 112-118.
69. Schone W, Ludwig M: A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993;13:34-39.
70. Walters G, Reynolds CF III, Mulsant BH, Pollock BG: Continuation and maintenance pharmacotherapy in geriatric depression: An open-trial comparison of paroxetine and nortriptyline in patients older than 70 years. J Clin Psychiatry 1999;60(suppl 20):21-25.
71. Zygmont M, Prigerson HG, Houck PR, Miller MD, Shear MK, Jacobs S, Reynolds CF II: A post-hoc comparison of paroxetine and nor-triptyline for symptoms of traumatic grief. J Clin Psychiatry 1998;59:241-245.
72. Tollefson GD, Bosomworth JC, Heiligenstein JH, Potvin JH, Holman S: A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995;7:89-104.
73. Evans M, Hammond M, Wilson K, Lye M, Copeland J: Placebo-controlled treatment trial of depression in elderly physically ill patients. Int J Geriatr Psychiatry 1997;12:817-24.
74. Altamura AC, Percudani M, Guercetti G, Invernizzi G: Efficacy and tolerability of fluoxetine in the elderly: A double-blind study versus amitriptyline. Int Clin Psychopharmacol 1989; 4:103-106.
75. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E: A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997;38:246-252.
76. Feighner JP, Cohn JB: Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiat 1985;46:20-25.
77. Falk WE, Rosenbaum JE, Otto MW, et al: Fluoxetine versus trazodone in depressed geriatric patients. Journal of Geriatric Psychiatry and Neurology 1989;2:208-214.
78. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, Refsum H-E, Ofsti E, Eriksson S, Syversen S: A controlled multicentre clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992;86:138-145.
79. Kyle CJ, Petersen HE, Overo KF: Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998;8:147-153.
80. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A nordic multi-centre study. Br J Psychiatry 1990;157:894-901.
81. Andersen G, Vestergaard K, Riis JO: Citalopram for post-stroke pathological crying. Lancet 1993;342:837-839.
82. Ragneskog H, Eriksson S, Karlsson I, Gottfries CG: Long-term treatment of elderly individuals with emotional disturbances: An open study with citalopram. Int Psychogeriatr 1996;8: 659-668.
83. Rahman MK, Akhtar MJ, Savla NC, et al: A double-blind randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br J Clin Pract 1991;45:255-258.
84. Wakelin JS: Fluvoxamine in the treatment of the older depressed patient: Double-blind placebo-controlled data. Int Clin Psychopharmacol 1986;1:221-230.
85. Phanjoo A, Wonnacott S, Hodgson A: Double-blind comparative multi-center study of fluvoxamine and mianserin in the treatment of major depressive episode in the elderly. Acta Psychiatr Scand 1991;83:476-479.
86. Arranz FJ, Ros S: Effects of comorbidity and polypharmacy on the clinical usefulness of sertraline in elderly depressed patients: An open multicentre study. J Affect Disord 1997;46: 285-291.
87. Hauser RA, Zesiewicz TA: Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12:756-759.
88. Goodnick PJ, Kumar A, Henry JH, Buki VM, Goldberg RB: Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997;33:261-264.
89. Cohn CK, Shrivastava R, Mendel SJ, et al: Double-blind multicentre comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990;51(suppl 8):28-33.
90. Dunbar GC: Paroxetine in the elderly: A comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology 1995;51:127-144.
91. Pollock BG: Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999;60(suppl 20):4-8.
92. Reimherr FW, Chouinard G, Cohn CK, Cole JO, Itil TM, Lapierre Y, Masco HL, Mendels J: Antidepressant efficacy of sertraline: A double-blind placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatry 1990; 51:18-27.
93. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I: Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-291.
94. Rasmussen SL, Overo KF, Tanghoj P: Cardiac safety citalopram: Prospective trials and retrospective analyses. J Clin Psychopharmacol 1999;19:407-415.
95. Kasper S: The pharmacokinetic profiles of SSRIs: Clinical relevance. Primary Care Psychiatry 1999;5:65-69.
96. Benfield P, Ward A: Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313-334.
97. Brosen K, Rasmussen BB: Selective serotonin re-uptake inhibitors: Pharmacokinetic and drug interactions; in Feighner JP, Boyer WF (eds): Selective Serotonin Re-Uptake Inhibitors. Advances in Basic Research and Clinical Practice. Chichester, Wiley, 1996, pp 87-108.
98. Salzman C: Management considerations for late-life depression. Primary Care Companion to J Clin Psychiatry 2000;2:33-36.
99. Khan A, Rudolph R, Baumel B, Ferguson J, Ryan P, Shrivastava R: Venlafaxine in depressed geriatric outpatients: An open-label clinical study. Psychopharm Bull 1995;31:753-758.
100. Dierick M: An open-label evaluation of the long-term safety of oral venlafaxine in depressed elderly patients. Ann Clin Psychiatry 1996;8:169-178.
101. Amore M, Ricci M, Zanardi R, Perez J, Ferrari G: Long-term treatment of geropsychiatric depressed patients with venlafaxine. J Affect Disord 1997;46:293-296.
102. Mahapatra SN, Hackett D: A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997;51:209-213.
103. Katona C, Bercoff E, Chiu E, Tack P, Versiani M, Woelk H: Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomised trial. J Affect Disord 1999;55:203-213.
104. Berzewski H, van Moffaert M, Gagiano CA: Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. Eur Neuropsychopharmacol 1997;7(suppl 1):S37-S47.
105. Halikas JA: Org 4770 (mirtazapine) versus trazodone: A placebo-controlled trial in depressed elderly patients. Hum Psychopharmacol 1995;10:S125-S133.
106. Thase ME: Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3,744 depressed patients, J Clin Psychiatry 1998;59:502-508.
107. Andreoli V, Carbognin G, Abati A, Vantini G: Reboxetine in the treatment of depression in the elderly: Pilot study. J Geriatr Psychiatry Neurol 1999;12:206-210.
108. Blythe D, Hackett LP: Cardiovascular and neurological toxicity of venlafaxine. Hum Exp Toxicol 1999;18:309-313.
109. Daniels RJ: Serotonin syndrome due to venlafaxine overdose. J Accid Emerg Med 1998; 15:333-334.
110. Fantaskey A, Burkhart KK: A case report of venlafaxine toxicity. J Toxicol Clin Toxicol 1995;33:359-361.
111. Kasper S: Treatment benefits of reboxetine. Int J Psychiatry Clin Pract 2001;3:3-8.
112. Bremner JD, Wingard P, Walshe TA: Safety of mirtazapine in overdose. J Clin Psychiatry 1998;59:233-235.